To summary, results from our meta-analysis show that the XRCC3 Thr241Met polymorphism can predict good response to platinum-based chemotherapy in patients with advanced NSCLC, especially in Caucasian population; while there is no significant association of XRCC3 Thr241Met polymorphism with survival of NSCLC. This evidence concerns the gene XRCC3 and non-small cell lung carcinoma.